Skip to main content

Dexcom Announces Continued Partnership with NASCAR Driver Ryan Reed

Dexcom, Inc., (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today that they are continuing their partnership with NASCAR driver Ryan Reed, the face of the American Diabetes Association’s national diabetes awareness initiative, Drive to Stop Diabetes℠ presented by Lilly Diabetes. Through the collaboration, Dexcom will continue its support of Ryan Reed while reinforcing the partners’ common quest of creating awareness of CGM among people with diabetes. The campaign highlights the importance of daily monitoring and tracking of glucose trends in the management of diabetes.

With nearly 10 percent of the American population currently living with diabetes, education on disease management is necessary.1 The rise of continuous glucose monitoring systems, like the Dexcom G4® PLATINUM, has helped patients with both type 1 and type 2 diabetes to understand valuable information about their glucose levels and trends.

“This initiative has made it possible for me to educate people who may be living with type 1 or type 2 diabetes about managing their disease and understanding their glucose levels. As an advocate for patients fighting the disease, it’s been important for me to actively inspire those who feel that they have to give up on their dreams after diagnosis,” says Ryan Reed, NASCAR driver. “With the help of my Dexcom G4® PLATINUM, I’ve never let diabetes slow me down.”

“We are very pleased to continue working with Ryan who has been such an inspiration to children and athletes all across America,” said Kevin Sayer, CEO of Dexcom. “For newly diagnosed patients, the ongoing challenge that comes with the disease can be very disheartening. Ryan’s success in a sport as demanding as auto racing shows people that anything is possible with the right management and mindset.”

CGM is an FDA-approved, physician-prescribed device that uses advanced technology to help people with diabetes to gain better control of their glucose levels. CGM is recommended by national diabetes clinical guidelines2 and most private insurance companies currently have policies that cover CGM for their patients with diabetes.

About Dexcom, Inc.

Dexcom, Inc., headquartered in San Diego, California, develops and markets continuous glucose monitoring systems for use by persons with diabetes, as well as blood glucose monitoring systems used by healthcare providers in hospital critical care settings. For more information on the Dexcom CGM, visit www.dexcom.com.

BRIEF SAFETY STATEMENT

The Dexcom G4® PLATINUM (Pediatric) Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (ages 2 to 17 years) with diabetes. CONTRAINDICATIONS: Remove the System before MRI, CT scan, or diathermy treatment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the System for treatment decisions. The System does not replace a blood glucose meter. In a pediatric clinical study, larger differences were observed between this CGM device and actual blood glucose values compared to those differences observed in the adult clinical study. Use your blood glucose meter for treatment decisions. In a pediatric clinical study, a significant number of low glucose events were not detected by CGM. Do not rely solely on CGM alerts to detect low glucose. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. The System is not approved for use in pregnant women or persons on dialysis. Sensor placement is not approved for sites other than under the skin of the belly or upper buttocks. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

References

1. Diabetes.org (http://www.diabetes.org/diabetes-basics/statistics/)

2. JDRF.org (http://jdrf.org/2014/11/a-personal-story-the-need-for-medicare-coverage-of-continuous-glucose-monitors-cgm/)

Contacts:

CONSUMER:
Green Room Public Relations
Candace Disler, 973–650-7975
Candace@greenroompr.com
or
INVESTOR:
Dexcom, Inc.
Steven Pacelli, 858-200-0200

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.